Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals

Related RIGL
Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
Earnings Scheduled For March 3, 2015

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL), and raised its price target from $14.00 to $21.00.

Jefferies noted, “RIGL reported 3Q12 earnings. RIGL continues to expect OSKIRA-4 Phase 2b results for fostamatinib (R788) in rheumatoid arthritis by YE2012 and OSKIRA-1-3 results in 1H13. We continue to believe in long-term upside for RIGL shares given the potential for fostamatinib and are increasing our estimates for the higher-than expected Xeljanz (oral competitor) pricing.”

Rigel Pharmaceuticals closed on Tuesday at $8.76.

Latest Ratings for RIGL

Mar 2014JefferiesMaintainsBuy
Jun 2013JefferiesMaintainsBuy
Jun 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (RIGL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters